Back to Search

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Recruiting Phase 1 Interventional Study
Advanced/Metastatic Solid Tumors Bladder Cancer Urothelial Carcinoma Advanced Non-Small Cell Lung Cancer Carcinoma, Non Small Cell Lung Carcinoma, Squamous Cell of Head and Neck Head and Neck Cancer Esophageal Cancer Gastroesophageal Junction Adenocarcinoma Esophageal Squamous Cell Carcinoma Esophageal Adenocarcinoma Pancreatic Adenocarcinoma Pancreatic Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
310 (estimated)
Sponsor
Pfizer · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given …
Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas * Measurable disease * ECOG Performance status 0-1 * Part 1: progression or relapse following standard treatments * Part 2: maximum of 2 prior lines of systemic therapy in th…
Contacts

Pfizer CT.gov Call Center

1-800-718-1021

ClinicalTrials.gov_Inquiries@pfizer.com

CONTACT

NCT ID: NCT07090499 Source: ClinicalTrials.gov